Product image of Icatibant Zentiva (Icatibant Acetate) supplied by GNH India

Icatibant Zentiva

Active Ingredient:
Icatibant Acetate
Origin:
EU

Icatibant Zentiva (Icatibant Acetate)

Icatibant acetate, the active ingredient in Icatibant Zentiva, is a bradykinin B2 receptor antagonist presented as a sterile injection solution for subcutaneous administration. It is indicated for the treatment of acute hereditary angioedema attacks in adult patients, providing rapid symptom relief by blocking bradykinin‑mediated vascular effects.

GNH India supplies Icatibant Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier, delivering the product to hospitals, pharmacies and clinics worldwide under stringent quality and regulatory standards. The product is sourced from the European Union market, ensuring compliance with EU pharmacopoeial specifications.

Manufacturer / TM Owner

Zentiva, K.S.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Icatibant Zentiva acts on the bradykinin pathway to treat hereditary angioedema attacks.

  • Hereditary angioedema type I: rapid reduction of swelling during acute attacks.
  • Hereditary angioedema type II: alleviates symptoms of sudden edema.
  • Hereditary angioedema with normal C1‑inhibitor: provides symptom control during attacks.

How It Works

  • Icatibant acetate selectively and competitively blocks the bradykinin B2 receptor on vascular endothelial cells. By preventing bradykinin binding, it inhibits the downstream signaling that causes vasodilation and increased vascular permeability, thereby reducing the swelling and pain associated with hereditary angioedema attacks.

Side Effects

Icatibant may cause a range of adverse reactions, most of which are related to the injection site or systemic exposure.

Common Side Effects

  • Injection site pain: discomfort at the subcutaneous injection site.
  • Injection site erythema: redness around the injection area.
  • Injection site swelling: localized edema.
  • Nausea: feeling of stomach upset.
  • Headache: mild to moderate head pain.
  • Dizziness: transient light‑headedness.

Serious or Rare Side Effects

  • Hypersensitivity reactions: rash, itching, or hives.
  • Anaphylaxis: severe allergic response requiring immediate medical attention.
  • Severe hypotension: marked drop in blood pressure.
  • Paradoxical angioedema: worsening swelling despite treatment.
  • Thrombocytopenia: reduced platelet count.
  • Injection‑site infection: signs of local infection such as warmth, pus, or fever.

Precautions & Warnings

Before using Icatibant, consider the following safety measures.

  • Pregnancy: safety not established; use only if potential benefit justifies the risk.
  • Breastfeeding: unknown safety; weigh maternal benefit against potential infant exposure.
  • Renal impairment: no dose adjustment required, but monitor renal function.
  • Concomitant ACE inhibitors: may reduce therapeutic effectiveness of icatibant.
  • Hypersensitivity: discontinue immediately if a severe allergic reaction occurs.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Icatibant can interact with other medicines that affect the bradykinin system or vascular tone.

Major Interactions (Avoid)

  • ACE inhibitors: may diminish icatibant's efficacy.
  • Angiotensin receptor blockers: similar potential to reduce therapeutic effect.
  • C1‑esterase inhibitor concentrates: concurrent use not recommended.

Moderate Interactions (Monitor Closely)

  • Estrogen‑containing oral contraceptives: may alter bradykinin levels.
  • NSAIDs: could increase risk of edema.
  • Antihistamines: may mask early signs of an allergic reaction.

Frequently Asked Questions

Icatibant Zentiva is used to treat acute attacks of hereditary angioedema (HAE) in adult patients. It works by rapidly reducing swelling and associated symptoms caused by excess bradykinin during an HAE episode.

Icatibant acetate is a selective competitive antagonist of the bradykinin B2 receptor. By blocking this receptor, it prevents bradykinin‑induced vasodilation and increased vascular permeability, which are the primary drivers of swelling in hereditary angioedema.

The dosage and administration schedule for Icatibant Zentiva are determined by the prescribing healthcare professional based on the patient’s clinical condition and response. The prescriber will set the appropriate dose and timing.

Safety data for icatibant acetate in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and necessary import documentation.

Icatibant is a bradykinin B2 receptor antagonist, whereas other approved HAE therapies include C1‑esterase inhibitor concentrates and kallikrein inhibitors. Icatibant acts directly at the receptor level, offering rapid symptom relief after subcutaneous injection, while the alternatives work upstream in the complement or kallikrein pathways.

Icatibant Zentiva must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution to maintain product stability.

The medication is supplied as a sterile injection solution for subcutaneous use. A healthcare professional injects the prescribed dose into the subcutaneous tissue, typically in the abdomen or thigh, following aseptic technique.

Serious risks include hypersensitivity reactions such as anaphylaxis, severe hypotension, paradoxical worsening of angioedema, and rare cases of thrombocytopenia. Patients should be monitored for any signs of allergic reaction or sudden blood pressure changes after administration.

Icatibant is contraindicated in individuals with known hypersensitivity to icatibant acetate or any of the formulation excipients. Patients with uncontrolled cardiovascular disease or those receiving ACE inhibitors or ARBs without medical guidance should avoid use until evaluated by a physician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Icatibant Acetate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT